USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hemodynamx-technologies Ltd.

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Hemodynamx-technologies ranks #35,682 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#35,682
of 49,997 US assignees by volume
36th percentile
by Innovation Score (30.9/100)
21.0
avg claims per patent
+150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35682 · Foreign Corporation #35,682 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 7 grants
  • MID-PACK #35,682/49,997
  • PHOTO-FINISH Heliovis
  • CPC-NARROW A61F · 3 areas
  • INNOV-THIN 30.9/100
  • CLAIMS-DENSE 21.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +150% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Heliovis AG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Hemodynamx-technologies

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Hemodynamx-technologies's Innovation Score is 30.9/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Hemodynamx-technologies's grants concentrate

Hemodynamx-technologies Ltd. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2020. By volume, Hemodynamx-technologies sits between Heliovis AG and Hermes Testing Solutions Inc..

Hemodynamx-technologies's three-year grant acceleration

Hemodynamx-technologies Ltd. shows 3 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Hemodynamx-technologies's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Hemodynamx-technologies holds 7 patents at rank #35,631, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Hemodynamx-technologies

By rank, the assignees closest to #35,631 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Hemodynamx-technologies's primary technology class.

Hemodynamx-technologies's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20192020202120222024 1
USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Hemodynamx-technologies Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 2 28.6%
2020 1 14.3%
2021 1 14.3%
2022 2 28.6%
2024 1 14.3%

Where it ranks

Overall rank by patents

#35,682

of 49,997 tracked assignees

Innovation Score

30.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Hemodynamx-technologies Ltd.'s patent record in context - here's where to go next.

  • Hemodynamx-technologies Ltd.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #35,682 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Hemodynamx-technologies Ltd. against Heliovis AG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 30.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.